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1. Introduction 
Hyaluronan (HA) is a non-sulfated linear glycosaminoglycan composed of multiple copies 
of the disaccharide unit of D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine 
(GlcNAc); [β-1,4-GlcA-β -1,3-GlcNAc-]n where n is the number of repeating disaccharide 
subunits. HA is synthesized by the HA synthase family of enzymes. Three HA synthases, 
termed HAS1 through HAS3, have been identified in humans and in mice. These enzymes 
differ from each other in their catalytic activities (HAS3 > HAS2 > HAS1) as well as in the 
sizes of their final products. HAS1 and HAS2 polymerize long stretches of GlcA-GlcNAc 
disaccharide chains, whereas HAS3 polymerizes relatively short stretches (<300 kDa). 
Biosynthesis of HA is regulated by exogenous stimuli. For example, HA synthesis in 
fibroblasts is upregulated by phorbol esters, tumor growth factor alpha, and platelet 
derived growth factor, whereas HA synthesis in keratinocytes is upregulated by retinoic 
acid, epidermal growth factor, and tumor growth factor alpha and suppressed by 
corticosteroids [1-4]. HA is unique among extracellular matrix components in that it is not 
synthesized within the cell and transported to the surface via vesicles. Hyaluronan 
synthase is an integral membrane protein on the surface of cells. It links together UDP-α-N-
acetyl-D-glucosamine and UDP-α-D-glucuronate to spin out long strands of HA. Because, 
unlike other extracellular matrix carbohydrates, HA is spooled out from the cell surface, it 
can achieve molecular weights ranging from five thousand Daltons to twenty million 
Daltons. 
Although HA was originally considered to be an inert filling material in the extracellular 
matrix and intercellular spaces, this simple carbohydrate is now known to have a number of 
functions in several different biological processes including development, cancer biology, 
wound healing and the immune response. 
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2. HA endocytic pathway 
A scheme for the endocytosis of high molecular weight HA (HMW-HA) and its catabolism 
to HA oligomers have been suggested previously [5]. Figure 1 illustrates the current model 
for uptake of HMW-HA and its processing to bioactive oligomeric fragments. 
HMW-HA in the extracellular matrix can be degraded to fragments that are 50-100 
saccharides in length by the HA digesting enzyme, hyaluronidase 2 (Hyal2) [6]. Hyal2 is 
expressed in the lysosome and also as a GPI-linked cell surface protein [7]. This raises the 
interesting question of how cell surface Hyal2 retains catalytic activity for HA digestion 
given its requirement for an acid environment to function. Previous investigations have 
shown that binding of HA to the HA-receptor, CD44, leads to the interaction of CD44 with 
the NHE1 Na+/H+ exchanger. In turn, the NHE1 Na+-H+ exchanger creates an acidic 
environment facilitating Hyal2 activity [8]. The HA saccharides generated by Hyal2 can then 
be endocytosed by one of multiple pathways. To date, receptor mediated endocytosis of HA 
and macropinocytosis of bulk phase HA have been reported. Receptor mediated 
endocytosis can occur via lipid rafts or by the clathrin coated pit pathway. Receptors for HA 
endocytosis may be recycled to the cell surface or turned-over. HA saccharides are further 
digested to HA oligosaccharides by hyaluronidase 1 (Hyal1) in the endosome. The HA 
oligosaccharides could then potentially be degraded into its GlcA and GlcNAc building 
blocks by the concerted activities of β-D-glucuronidase and β-N-acetyl-D-hexosaminidase 
[9] or HA oligosaccharides could be exocytosed. The exocytosed HA fragments could have 
myriad biological functions which will be detailed below. 
Although HA endocytosis and subsequent degradation may be important for generation of 
bioactive HA fragments, the HA endocytic pathway is also essential for HA homeostasis. In 
a 70 kilogram human there is approximately 15 grams of total HA [10]. Up to 50% of the 
total HA in the body is expressed in the skin [11]. HA is turned over at a rate of 
approximately 5 grams per day [10]. In the skin, HA has a metabolic half-life <1.5 days [11]. 
HA is turned-over locally in tissues while systemic HA is cleared mostly in the liver and to a 
lesser extent the kidneys and spleen [12,13]. HA in the tissue extracellular matrix is thought 
to be partially degraded and then enters the lymph nodes via the draining lymphatics. 
Specific HA receptors in the lymphatics will be discussed below.  
3. Mechanisms of hyaluronan endocytosis 
3.1. Receptor mediated endocytosis 
Uptake of hyaluronan by various receptors has been widely studied, and several key 
receptors have been identified. Some receptors, such as CD44 and LYVE-1, serve dual 
purposes in that they not only facilitate the endocytosis of HA, but also trigger signaling 
events that generate cell specific responses to HA binding. ICAM-1 was initially believed to 
serve as a metabolic receptor for HA only but is now suspected to have cell signaling roles 
in response to HA binding [14,15].  
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3.1.1. CD44 
CD44 is a cell surface glycoprotein that serves as the endocytic receptor for HA in 
keratinocytes, chondrocytes, and breast cancer cells [16-18]. It is important to stress that the 
binding of HA to CD44 and the uptake of HA by CD44 mediated endocytosis are two 
separate events that often do not take place at the same time [19]. Internalization of HA 
through CD44 mediated endocytosis has been shown to require acylation of the CD44 
cytoplasmic tail [20]. CD44 associates with lipid rafts for internalization as determined by 
gradient ultracentrifugation. Palmitoylation of CD44 on two cysteine residues, Cys286 in the 
transmembrane domain and Cys295 in the cytoplasmic domain, was found to be essential for 
lipid raft association, but not for HA binding. These acylation reactions could be cell type 
specific, which may explain why CD44 does not endocytose HA in all CD44 expressing cell 
types, such as B16-F10 melanoma cells [19]. There is also evidence that CD44 interacts 
directly with endocytosis proteins such as coatomer protein complexes [21]. Previous 
investigations have suggested that endocytosed CD44 can be recycled to the cell surface 
provided it is not ubiquitinated after endocytosis [22]. Recent studies in fibroblasts have 
shown that clathrin-independent carriers (CLIC) form an endocytic sorting system at the 
leading edge of migrating cells. Adhesion molecules, including CD44, are recycled in the 
CLIC pathway. CD44 and other CLIC cargo are concentrated within flotillin-1 and 
cholesterol enriched microdomains. Actin and GRAF-1 form the initial carriers within 15 
seconds. Next, Rab11 and Rab5 / EEA-1 complexes allow bulk membrane flow to early 
endosomes and plasma membrane recycling [23]. It is tempting to speculate that the CLIC 
pathway in CD44 recycling is also involved in HA endocytosis. 
3.1.2. RHAMM 
The Receptor for Hyaluronic Acid Mediated Motility (RHAMM) was discovered originally 
as a soluble protein that altered the migration of cells and could bind HA [24]. RHAMM has 
no cytoplasmic or transmembrane domain and has no signaling domains, but it has been 
implicated in ERK1/2 signaling through a complex with CD44 upon HA binding [25]. 
RHAMM is also found in the cytoplasm where it associates with the mitotic spindle 
apparatus, which is responsible for establishing cell polarity and distribution of 
chromosomes during mitosis [25]. RHAMM can be transported out of the cytoplasm to the 
cell surface. In terms of RHAMM endocytosis, very little is known. By contrast, a number of 
studies have shown a role for RHAMM in tumor progression and the differentiation of 
osteoblasts [26,27]. As it is known that CD44 and RHAMM can associate with each other 
and that RHAMM binds HA, it is possible that RHAMM/CD44/HA complexes can be 
endocytosed or leads to signaling. There is evidence that RHAMM and CD44 co-signal 
through the ERK1/2 pathway to increase basal motility in breast cancer cells and increase 
fibroblast migration and differentiation during wound repair [28,29]. 
3.1.3. LYVE-1 
Lymphatic vessel endothelial-1 (LYVE-1) is expressed on the surface of lymphatic 
endothelial cells. Interestingly, LYVE-1 has a glycosylation domain on its extracellular 
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domain that renders it inactive. Cleavage of this glycosylated region allows LYVE-1 to bind 
HA [30]. The LYVE-1 binds HA which is then bound by leukocyte CD44 in order to facilitate 
their adhesion and entry into the lymphatics [31]. Not much is known about the 
mechanisms of LYVE-1 endocytosis of HA, but it is thought to occur similarly to CD44 
mediated uptake of HA; i.e., LYVE-1 associates with lipid rafts before endocytosis [31]. 
LYVE-1 may be responsible for the transport of HA to the luminal side of the lymphatics. It 
has previously been shown that LYVE-1 binds to HA on the lymphatic endothelial cells, 
endocytosis of the complex occurs, and then the vesicles are released on the lumen side of 
the lymphatics allowing for release of HA which can possibly modulate immune responses 
or mediate removal of HA from the lymph for clearance [32]. Importantly, the lymph nodes 
are the first sites of clearance for total body HA turn-over. In fact, about 85% of total body 
HA is cleared by the lymph nodes. The remaining HA is largely turned over in the liver [33]. 
3.1.4. HARE 
Hyaluronan Receptor for Endocytosis (HARE) is expressed on sinusoid hepatocytes, the 
venous sinuses of the red pulp in spleen and the medullary sinuses in lymph nodes where it 
is important for the turnover of systemic HA [34]. Indeed, blocking HARE results in an 
inhibition of HA clearance in the liver [35]. HARE also plays a role in chondroitin sulfate 
proteoglycan endocytosis [36]. Previous investigations infer that HARE endocytosis occurs by 
the clathrin coated pit pathway and it appears that HARE is recycled to the cell surface [37]. 
Binding of HARE to HA was observed using ligand blotting and immunohistochemistry 
which shows that the HARE HA binding event occurs prior to HA internalization [38]. Four 
putative AP-2 / clathrin mediated endocytosis signaling domains have been identified in the 
HARE cytoplasmic domain: YSYFRI2485, FQHF2495, NPLY2519, and DPF2534 (315-HARE 
numbering). Deletion analyses of the signaling domains showed that three signal sequences 
(YSYFRI, FQHF, and NPLY) provide redundancy to mediate coated pit targeting and 
endocytosis of HARE. Importantly, the coated pit targeting domains did not impact binding 
of the HARE ectodomain to HA showing that HA binding to HARE and HARE mediated 
endocytosis of HA are separate events [39]. 
It is noted that HARE and LYVE-1 are both expressed in the lymph nodes. Interestingly, 
HARE and LYVE-1 show different and non-overlapping distributions [33]. How and if 
LYVE-1 and HARE coordinate HA turn-over remains to be determined. 
3.1.5. ICAM-1 
Intercellular adhesion molecule 1 (ICAM-1) is perhaps the least studied of the receptors for 
HA. It appears not to facilitate HA endocytosis but rather, it is a receptor for HA that has 
signaling capacity. Preliminary data suggests that ICAM-1 functions as a signaling molecule 
when HA binds to it. When HA is added to the macrophage cell line U937, it induces Akt 
phosphorylation which activates the nuclear factor-kappa B pathway, inducing interleukin-
6 production, but blocking of ICAM-1 with an antibody stops this from occurring [14,15].  
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3.2. Non-receptor mediated endocytosis 
3.2.1. Macropinocytosis of hyaluronan 
It has been demonstrated that HA uptake can occur without the aid of endocytic receptors. 
In [19], it was determined that B16-F10 melanoma cells endocytosed HA through 
macropinocytosis. The cells were observed to display membrane ruffling and localization of 
HA within vesicles as well as strong co-localization of HA with fluorescently labeled 
dextran, a macropinocytosis tracer. The uptake was also inhibited by amiloride, an inhibitor 
of macropinocytosis. Interestingly, the B16-F10 melanoma cells expressed surface CD44. 
Moreover, CD44 mediated adhesion of the melanoma cells to HA-coated plates. On the 
other hand, removal of CD44 from the B16-F10 melanoma cells by proteolytic cleavage 
failed to impact HA uptake. These results showed that CD44 did not play a significant role 
in the endocytosis of soluble HA. As mentioned in the previous section, the uptake of HA 
by CD44 requires CD44 to be in a specific state. It is possible, through splice variants of 
CD44, that these modifications were not present, and that there are distinct pathways in 
which HA can be taken up by cells. The ability of HA to induce macropinocytosis in B16-F10 
melanoma cells is most likely due to its ability to non-specifically interact with the cell 
surface. HA has been shown to interact with and cause rearrangement of the cell surface 
[40]. [41] also showed that blocking of CD44 failed to inhibit the uptake of HA by 10T1/2 
fibroblasts. 
4. Potential biological functions of endocytosed HA 
As shown in Figure 1, HA oligomers are produced by degradation of HA following its 
endocytosis. On the other hand, most studies on the biological activities of HA have been 
performed by adding exogenous HA oligomers to cell cultures and then determining their 
effect on biological activity. Presumably, HMW-HA co-polymers are endocytosed and 
digested and the resulting low molecular weight-HA (LMW-HA) fragments exocytosed 
under physiological conditions. Indeed, the hyaluronidase inhibitor apigenin resulted in 
accumulation of HA in pre-lysosomal endosomes in rat keratinocytes in vitro [18]. On the 
other hand, direct evidence for exocytosis of HA fragments are currently lacking. It is 
important to note that in some cases, the hyaluronidases may be secreted into the 
extracellular matrix or in the case of Hyal-2, expressed on the cell surface. HA degrading 
activity can also be exocytosed [42]. Obiviously, secreted hyaluronidase and cell surface 
Hyal-2 could circumvent the requirement for endocytosis.  
4.1. Cell activation via HA 
A number of investigators have reported that LMW-HA can induce molecular pathways 
culminating in gene expression. [43] has shown that oligomeric HA stimulated various 
transcription factors in chondrocytes including Sp1 and NF-κB. The same group showed that 
HA oligosaccharides induce expression of matrix metalloproteinase 13 by p38 MAPK and 
transcriptional activation of NF-κB [44]. It has also been shown that HA oligosaccharides  
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HMW-HA (~106Da) is first degraded by hyaluronidase 2 (HYAL2) into smaller 104Da sized fragments before it is taken 
up by a cell. The cell can either utilize surface HA receptors for receptor mediated endocytosis or macropinocytosis. 
Once internalized the HA is degraded by hyaluronidase 1 (HYAL1) into small 102Da fragments and then exocytosed. 
Figure 1. Schematic overview of HA endocytosis and processing. 
inhibit the expression of runt-related gene 2 (Runx2) in chondrocytes. Runx2 is a 
transcription factor for chondrocyte differentiation in hypertrophic chondrocytes [45,46]. 
Thus, HA oligosaccharides may impact the differentiation of chondrocytes during 
endochondrol ossification. [46] showed that binding of HA fragments to the HA receptor 
CD44 induces the Nanog-Stat-3 signaling pathway culminating in expression of the 
multidrug resistance gene, MDR-1, in breast and ovarian tumor cells. Expression of MDR-1 
in the tumor cells conferred resistance to chemotherapeutic drugs doxorubicin and 
paclitaxel. Finally, it has been shown that LMW-HA upregulated CD44 expression and 
increased the expression levels of PKCδ and PKCϵ [47]. 
4.2. Cancer cell invasion and metastasis 
Controversy has surrounded the role of the hyaluronidase enzymes in tumor biology with 
initial reports suggesting that Hyal1 was a tumor suppressor [48]. Early positional cloning 
studies identified the Hyal1 locus on 3p21.3 with LuCa1 (Lung Cancer 1). Because LuCa1 
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was either deleted or there was a loss in heterozygosity in LuCa1 in most lung cancers, it 
was hypothesized that Hyal1 behaved as a tumor suppressor. However, subsequent studies 
showed that Hyal1 was not the relevant tumor suppressor at the examined locus [49]. 
Nonetheless, the suppressive activity of hyaluronidses was confirmed by investigations 
showing that administration of high doses (300 U) of PH20 to mice with human breast 
tumor xenografts showed a significant reduction in tumor growth [50]. The over-expression 
of Hyal1 in a rat colon carcinoma line also inhibited tumor growth further suggesting that 
Hyal1 is a tumor suppressor [51]. 
Groundbreaking work by [52] showed that Hyal1 promoted tumor growth, invasion and 
angiogenesis. On the other hand, overproduction of Hyal1 to high levels (100 mU / 106 cells) 
inhibited tumor growth. These results suggested that high concentrations of Hyal1 may 
result in tumor inhibition while at lower levels Hyal1 leads to tumor progression. 
Previous studies have shown that anti-sense Hyal1 stably expressed in bladder and prostate 
cancer cells induced down regulation of cdc25c, cyclin B1, cdk1 and cdk1 kinase activity 
[52,53]. Expression of Hyal1 in oral carcinoma cells resulted in a dramatic increase in cells in 
S-phase and a decrease in the number of cells in the G0-G1 phase [54]. To date, the 
mechanism whereby Hyal1 promotes tumor cell growth remains unknown. On the other 
hand, treatment of mouse fibroblasts with PH20 leads to phosphorylation of JNK-1 and -2 as 
well as p42 / p44 ERK [55]. Importantly, ERK plays a role in the G1-S transition [56]. 
The activities of the hyaluronidase enzymes also appear to have roles in the biology of 
malignant melanoma (MM) tumors. [57] found that aberrant expression of PH20 by MM 
cells was correlated with their induction of angiogenesis in a mouse model. Histological 
studies of MM showed that tumor associated HA expression was correlated with patient 
survival with low HA levels showing poor prognosis [58]. Because the activities of HA 
synthesis (by the HAS enzymes) and HA degradation (by the hyaluronidase enzymes) is 
highly regulated and may be interconnected, these results might suggest that an imbalance 
in HA metabolism in MM tumors may lead to cancer progression in humans. 
Hyaluronidase activity has also been evaluated as a biomarker in bladder cancer. Tumor 
associated Hyal1 is released into the urine of bladder cancer patients [59]. Urinary 
hyaluronidase activity was elevated in patients with intermediate and high grade bladder 
cancer as compared with patients with: a) low grade bladder cancer, b) patients with a 
history of bladder cancer, c) normal individuals, and d) patients with benign urologic 
conditions [60]. These findings underscore the potential utility of the hyaluronidases to 
serve as biomarkers for cancer grading. 
4.3. Wound healing  
Tissue contraction during wound healing is achieved by myofibroblasts. Fibroblasts 
differentiate into myofibroblasts which line up at the edges of the wound and adhere to each 
other with desmosomes. They then use their actin networks to contract the ECM around the 
wound and shrink the size of the wounded area. Fibroblasts in the area around the wound 
then secrete collagen to stabilize the contraction. The trigger for contraction is HA production, 
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and HA plays a key role in regulating this process by directing fibroblast migration and 
proliferation at wound sites [61].  
HA’s role in wound healing is not clearly understood, but it is known that in a fetal state, as 
compared to an adult state, the extracellular matrix is composed of primarily HA. This 
abundance of HA rather than collagen reduces scar formation. CD44 mediated endocytosis 
of HA fragments also aids fibroblasts in migration to wound sites [62].  
5. Applications of hyaluronan endocytosis 
5.1. Drug delivery 
HA may allow the targeted delivery of chemotherapeutic reagents to tumor cells via CD44. 
HA have a number of functional groups for “decoration” including a carboxylate on the 
glucuronic acid, the N-acetylglucosamine hydroxyl and the reducing end. Thus, a wide 
array of different chemotherapeutic reagents can be chemically conjugated to HA. A review 
of the chemical derivatization of HA and the potential applications of HA to disease 
treatment is beyond the scope of this chapter but has been recently reviewed [63,64]. In 
brief, previous investigations in vitro showed that a taxol-HA bioconjugate was cytotoxic to 
a panel of tumor cell lines (breast, colon and ovarian) but not human fibroblasts [65]. 
Although there are relatively few in vivo studies that have evaluated the efficacy of HA 
bioconjugates, previous investigations with a paclitaxol-HA bioconjugate have shown that it 
inhibits tumor growth of RT-112/84 human transitional cell carcinomas in mice and 
increases the survival of mice that had been inoculated with the NMP-1 or SK-OV-3ip 
human ovarian carcinoma lines [66,67]. Similarly, a butyrate-HA bioconjugate was found to 
inhibit tumor growth and reduced lung metastasis in mice inoculated with LL3 murine lung 
carcinoma cells [68]. Thus, a number of reports reinforce the concept that HA may be useful 
as a drug carrier / ligand targeting delivery agent. Other investigators conjugated 
doxorubicin, a chemotherapeutic agent, to HA and administered it topically to B16-F10 
melanoma tumors in mice [69]. They found that doxorubicin-conjugated HA selectively 
targeted the tumor cells and reduced tumor growth. These findings open the door for future 
work with drug delivery to tumor cells using HA. 
HA may also be a useful carrier of carboranes for boron neutron capture therapy for tumors. 
Previous investigations have shown that a water soluble HA-polycarborane derivative was 
taken up and showed toxicity to a number of tumor cell lines in vitro [70]. 
5.2. Imaging  
HA may also be derivatized for imaging tumor cells. An activatable HA molecular probe, 
called FRET-HA, designed to detect hyaluronidase activity was recently reported [71]. 
Briefly, the HA co-polymer was chemically labeled with donor and acceptor fluorescent 
probes. Energy transfer from the donor to acceptor probe resulted in quenching of the 
acceptor (i.e., fluorescence resonance energy transfer or FRET). Because energy transfer is 
distance dependent, an increase in the distance between the donor and acceptor probes, for 
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example due to HA degradation, results in de-quenching of the donor. The rate of donor 
fluorescence change was used to determine the enzyme kinetics of bovine testes 
hyaluronidase with high precision and accuracy. FRET-HA has also been used to detect 
hyaluronidase activity in B16-F10 melanoma cells in vitro (unpublished results). The 
potential utility for FRET-HA to detect increased hyaluronidase activities in vivo is 
currently under investigation. 
Recently, HA has been coated onto superparamagnetic iron oxide nanoparticles [72]. These 
HA-coated nanoparticles were endocytosed by cancer cells allowing their magnetic 
resonance imaging in vitro. 
6. Conclusion 
HA is a glycosaminoglycan with diverse biological functions. The molecular weight of HA is 
important for dictating its biological functions with HA fragments inducing distinct responses 
from high molecular weight co-polymers. Endocytosis of HA via receptor dependent and 
independent pathways is likely required for digestion of HA to biologically active fragments. 
In addition, endocytosis of HA may be exploited for the uptake of chemotherapeutic drugs for 
cancer treatment or imaging probes for the detection of metastatic tumors. Future directions 
include, 1) better understanding of the endocytic mechanism for HA metabolism, 2) better 
understanding of HA receptor signaling and interactions and 3) the development of second 
generation HA scaffolds for delivery and medical imaging. 
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